Posted in | Nanomedicine

Nanocarriers to Deliver Drugs for Inflammatory Bowel Disease Treatment

CEA-Leti recently unveiled a program to use a nanocarrier-based method to help treat inflammatory bowel disease. The Delivering Nano-pharmaceuticals through Biological Barriers project, BIBA, has eight collaborators in France, Germany, Spain and Switzerland.

CEA-Leti co0ordinates the program as an initiative of its research program on organic nanocarriers and delivery solutions for clinical applications such as molecular imaging and drug delivery.

The three-year research will help create an anti-inflammatory corticoid and an immunosuppressant confined in a biodegradable nanocarrier to treat IBD while minimizing side effects. Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD). Corticosteroid is used to cure it and an immunosuppressant is used to avoid relapses. But over 70% of CD cases and 20% of UC ones are not cured and need surgery. Corticosteroids such as prednisolone can bring remission in 60 to 80% patients. Prolonged treatment also causes side effects.

The project will research on delivery of encapsulated corticosteroids and immunosuppressants with two organic biodegradable nanocarriers in an endeavor to avoid side effects. Passive targeting of nano-delivery systems in swollen tissues use the enhanced permeability and retention (EPR) to increase corticoïds collection in inflamed areas.

One model, each of corticoid, budesonide and immunosuppressant, cyclosporine, will be individually administered in three dosage forms including oral, colonic, and intravenous, to optimize anti-inflammatory drug delivery across the gastrointestinal tract, with lipid baby bubbles (Lipidots) and poly(lactic-co-glycolic acid) (PLGA) particles used as nanocarriers. Laboratory tests on animal models will be conducted on a healthy and pathological epithelium to identify relevant nano-pharmaceuticals. Non-invasive MRI and optical fluorescence with histological tests will help study the therapy results on the inflamed mucosa.

The study has received grants from the European programme ERANET EuroNanoMed.

Source: http://www.leti.fr.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 12). Nanocarriers to Deliver Drugs for Inflammatory Bowel Disease Treatment. AZoNano. Retrieved on July 18, 2019 from https://www.azonano.com/news.aspx?newsID=22224.

  • MLA

    Chai, Cameron. "Nanocarriers to Deliver Drugs for Inflammatory Bowel Disease Treatment". AZoNano. 18 July 2019. <https://www.azonano.com/news.aspx?newsID=22224>.

  • Chicago

    Chai, Cameron. "Nanocarriers to Deliver Drugs for Inflammatory Bowel Disease Treatment". AZoNano. https://www.azonano.com/news.aspx?newsID=22224. (accessed July 18, 2019).

  • Harvard

    Chai, Cameron. 2019. Nanocarriers to Deliver Drugs for Inflammatory Bowel Disease Treatment. AZoNano, viewed 18 July 2019, https://www.azonano.com/news.aspx?newsID=22224.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit